

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

SECTION 1. IDENTIFICATION

Substance name : Amivantamab HC CF, CNTO 4424 (Drug Product)

Rybrevant FASPRO

Reference number : JNJ-61186372-AAA

Manufacturer or supplier's details

Company name of supplier : Janssen Pharmaceuticals, Inc.

Address : 1125 Trenton-Harbourton Rd

Titusville NJ 08560

USA

Telephone : +16097302000

E-mail address of person responsible for the SDS

SDSJanssen@its.jnj.com

Emergency telephone

: CHEMTREC US: 1-800-424-9300

number

CHEMTREC International: +1 703-741-5970

Recommended use of the chemical and restrictions on use

Recommended use : Large Molecule Pharmaceutical intended for medical use.

Bispecific/Multispecific antibody

For research use only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

Avoid direct contact and significant aerosol/dust exposure which has the remote possibilities of eliciting an allergic response. May cause sensitization in susceptible persons.

This material is not likely to be significantly absorbed via occupational routes of entry due to its chemical structure and large molecular weight.

May damage the developing embryo/fetus if administered parenterally at therapeutic concentrations.

Maternal systemic exposure from worker handling is expected to be negligible and embryo/fetal harm from worker exposure is considered unlikely.



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Chemical nature : Liquid

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|----------------------------------|--------------|-----------------------|
| JNJ-61186372-AAA | Not Assigned | >= 10 - < 20 |
| alpha-D-Glucopyranoside, beta-D- | 57-50-1 | >= 5 - < 10 |
| fructofuranosyl | | |

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : This material is being evaluated for use as a biological agent

or in the manufacturing of a biological agent.

If accidently injected (needle prick or through broken skin):

Stimulate bleeding for approximately 5 minutes. Wash off immediately with soap and plenty of water.

Call a physician immediately.

If inhaled : If breathed in, move person into fresh air.

Rinse nose and mouth with salt water.

Call a physician immediately.

In case of skin contact : Take off contaminated clothing and shoes immediately.

Wash off immediately with plenty of water. If skin irritation persists, call a physician.

Consult a physician.

Process contaminated clothing and PPE's according to hospital procedures in accordance with applicable waste

disposal regulations.

In case of eye contact : Remove contact lenses.

Rinse immediately with plenty of water, also under the eyelids,

for at least 15 minutes. Call a physician immediately.

If swallowed : Do NOT induce vomiting.

If swallowed, rinse mouth with water (only if the person is

conscious).

Drink plenty of water.

Call a physician immediately.

Product is digested in the GI tract and unlikely to be systemically absorbed in significant amounts.

Most important symptoms

and effects, both acute and

delayed

Adverse effects via parenteral drug administration may include

Rash

Infusion reactions musculoskeletal pain

Nausea Fatigue



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

Oedema Cough constipation Vomiting Pneumonia

Notes to physician : Treat symptomatically.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local

circumstances and the surrounding environment.

Specific hazards during

firefighting

The product is not flammable.

Further information : No information available.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures In the event of an accidental release the emergency response team must respond based on a risk assessment and use

personal protective equipment as appropriate.

Avoid direct contact with broken glass, plastic and other

sharps.

Avoid splashes and spray formation. Evacuate personnel to safe areas.

Avoid direct contact and significant aerosol exposure.

Environmental precautions : Should not be released into the environment.

Methods and materials for containment and cleaning up

Small spills: Gently cover the spill with an absorbent towel or

pad.

Wet absorbent pad with 10% bleach solution. Allow 30

minutes contact time.

Large spills: Allow the dust/aerosol to settle for 30 minutes or

use appropriate respiratory protection.

Dam up.

Soak up with inert absorbent material.

Add bleach (5.25% sodium hypochlorite) solution to a final liquid concentration of 10% (1 part bleach, mixed with 9 parts liquid) to absorbent materials. Allow 30 minute contact time. Large spills + Small spills: Keep in suitable, closed containers for disposal. Treat recovered material as described in the

section "Disposal considerations".

Clean up with a 10% bleach (5.25% sodium hypochlorite) solution, 1 part bleach, mixed with 9 parts water is recommended for cleaning of surfaces and equipment. Clean spill location and adjacent surfaces thoroughly with



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

ethanol or water with detergent.

Special consideration may need to be evaluated based on

specific hazards.

SECTION 7. HANDLING AND STORAGE

Advice on protection against :

fire and explosion

The product is not flammable.

Advice on safe handling : Avoid splashes.

Avoid formation of aerosol.

Avoid inhalation, ingestion and contact with skin and eyes. Avoid any unintended exposure by accidental needle

prick/stick.

Do not heat the product.

Use personal protective equipment as required.

Conditions for safe storage : To maintain product quality, do not store in heat or direct

sunlight.

Store in original container.

Keep containers tightly closed in a dry, cool and well-

ventilated place.

Keep away from fire, sparks and heated surfaces.

Keep locked up.

Recommended storage

temperature

36 - 46 °F / 2 - 8 °C

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--|--|-------------------------------------|--|-------------------------|
| JNJ-61186372-AAA | Not Assigned | PBOEL-HHC | 2 | J&J OEL/PBOEL HHC |
| | Further information: J&J has a hazard banding notation: PBOEL HHC. This substance is classified by J&J as being PBOEL HHC 2. This means that the OEL is estimated to be from 20 to 100 µg/m3 | | | |
| alpha-D-Glucopyranoside, beta-D-fructofuranosyl | 57-50-1 | TWA | 10 mg/m3 | ACGIH |
| | | TWA (Respirable) | 5 mg/m3 | NIOSH REL |
| | | TWA (total) | 10 mg/m3 | NIOSH REL |
| | | TWA (total dust) | 15 mg/m3 | OSHA Z-1 |
| | | TWA (respirable fraction) | 5 mg/m3 | OSHA Z-1 |



| Version | Revision Date: | SDS Number: | Date of last issue: 2024/12/03 |
|---------|----------------|--------------|---------------------------------|
| 1.21 | 2025/09/05 | 100000016156 | Date of first issue: 2020/10/29 |
| | | | |

| TWA (Total dust) | 15 mg/m3 | OSHA P0 |
|----------------------------|----------|---------|
| TWA | 5 mg/m3 | OSHA P0 |
| (respirable dust fraction) | | |

Engineering measures : All personal protective equipment should be based on a risk

assessment. Consult a Environment Health Safety expert if

necessary.

Personal protective equipment

Respiratory protection : Engineering controls should always be the primary method of

controlling exposures.

There is remote possibility that this product could be

aerosolized and inhaled in the workplace.

If respiratory protective equipment is needed for certain activities, the type as well as the corresponding protection factor will depend upon the risk assessment and air

concentrations, hazards, physical and warning properties of

substances present.

Hand protection

Remarks : Disposable gloves

Eye protection : Safety glasses

Skin and body protection : Lab coat

Protective measures : The type of protective equipment must be selected based on

the Environmental Health and Safety risk assessment. Consult a Environmental Health and Safety expert if

necessary.

Hygiene measures : Handle in accordance with good industrial hygiene and safety

practice.

Avoid use of sharps, utilize safe-engineered sharps or non-

penetrable gloves, where appropriate.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : colourless

pH : 5.7

Flash point : No data available

Flammability (solid, gas) : The product is not flammable.

Density : 1,074 g/cm3 (68 °F / 20 °C)



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

SECTION 10. STABILITY AND REACTIVITY

Reactivity : None reasonably foreseeable.

Chemical stability : Stable under recommended storage conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid : To avoid thermal decomposition, do not overheat.

Exposure to sunlight.

Incompatible materials : No data available

Hazardous decomposition

products

None known.

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

Product:

Remarks : Large protein biotherapeutics in the dry or reconstituted

(solution in buffer) forms are not expected to elicit skin corrosion/irritation, skin sensitization, or cause damage

to/irritate the eyes.

Assessment : Single-dose acute toxicity studies were not performed. This

product is a large protein biotherapeutic intended for injection. It is not expected to be absorbed via the oral, dermal, or

inhalation routes of exposure.

Germ cell mutagenicity

Product:

Germ cell mutagenicity -

Assessment

Routine genotoxicity studies are not applicable to

biotherapeutics as large proteins cannot diffuse into cells and

interact with DNA or chromosomal material.

Carcinogenicity

Product:

Remarks : Not applicable



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

Carcinogenicity - Assessment : Carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with

advanced cancer.

IARC No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No component of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Product:

Effects on fertility : Species: Monkey, male and female

Dose: 120 milligram per kilogram

Remarks: No significant adverse effects were reported No effect on fertility endpoints was observed in non-human

primates.

Effects on foetal development

Remarks: No data available

Reproductive toxicity -

Assessment

This product is a bispecific antibody composing cMet. cMet is a receptor tyrosine kinase inhibitor which is known to be teratogenic at therapeutic concentrations., As maternal systemic exposure from handling is expected to be negligible and placental transfer of monoclonal antibodies in humans is very low during the period of organogenesis (1st trimester), embryo/fetal harm from worker exposure is considered unlikely., Weight of evidence does not support classification

for reproductive toxicity

STOT - single exposure

No data available

STOT - repeated exposure

No data available

Repeated dose toxicity

Product:

Species : Non-human primate

NOAEL : 120 mg/kg

Application Route : intravenous injection

Exposure time : 13 weeks
Number of exposures : weekly

Dose : 20, 60, 120 mg/kg

Remarks : No significant adverse effects were reported

Repeated dose toxicity -

Assessment

Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection.



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

It is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.

Aspiration toxicity

No data available

Experience with human exposure

No data available

Toxicology, Metabolism, Distribution

No data available

Neurological effects

No data available

Further information

No data available

Other health hazards

No data available

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : In accordance with National, Federal, State and Local

regulations.

Decontaminate all waste (i.e. steam sterilization/autoclaving, chemical disinfection) before disposal or ensure incineration of

medical waste as a proper disposal route

SECTION 14. TRANSPORT INFORMATION

International Regulations



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

US State Regulations

Massachusetts Right To Know

alpha-D-Glucopyranoside, beta-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know

water 7732-18-5
JNJ-61186372-AAA Not Assigned alpha-D-Glucopyranoside, beta-D-fructofuranosyl 57-50-1

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

New York City Hazardous Substances

edetic acid 60-00-4

California Permissible Exposure Limits for Chemical Contaminants

alpha-D-Glucopyranoside, beta-D-fructofuranosyl 57-50-1

Other regulations

Restricted to professional users.

Biosafety Regulations and Guidelines:

World Health Organization, Laboratory biosafety manual. - 4 th ed., ISBN 9789240011311, 2020, pp. 124.

OSHA Bloodborne Pathogen Standard 29 CFR 1910.1030 and the OSHA Standard Interpretation on Applicability of 1910.1030 to Establish Human Cell Lines;

U.S. Department of Health and Human Services Public Health Services, Biosafety in Microbiological and Biomedical Laboratories (BMBL) - 5th ed., HHS Publication No. (CDC) 21-1112



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

J&J OEL/PBOEL HHC : J&J OEL/PBOEL HHC

NIOSH REL : USA. NIOSH Recommended Exposure Limits

PBOEL-HHC

OSHA P0 : USA. Table Z-1-A Limits for Air Contaminants (1989 vacated

values)

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1

Limits for Air Contaminants

ACGIH / TWA : 8-hour, time-weighted average

J&J OEL/PBOEL HHC /

PBOEL-HHC

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA P0 / TWA : 8-hour time weighted average OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials: bw - Body weight: CERCLA - Comprehensive Environmental Response. Compensation, and Liability Act: CMR - Carcinogen, Mutagen or Reproductive Toxicant: DIN -Standard of the German Institute for Standardisation: DOT - Department of Transportation: DSL -Domestic Substances List (Canada): ECx - Concentration associated with x% response; EHS -Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx -Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA -International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO -International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship: RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/12/03

 1.21
 2025/09/05
 100000016156
 Date of first issue: 2020/10/29

For research use only.

Revision Date : 2025/09/05

Date and Number Formats

This document uses the following notation for printing dates and numbers:

Date: Dec 31th, 2012 as 2012/12/31

Numbers: 123456,78 as 123,456.78

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN